Dublin, Ireland, 29 September, 2006 - AGI Therapeutics plc (AIM, IEX: AGI, “AGI” or the “Company”), a speciality pharmaceutical company focused on gastrointestinal (GI) drug products, today announces the preliminary results of a phase II trial of the Company’s espindolol (AGI-001) product candidate for the treatment of irritable bowel syndrome (IBS).
